Xinping Zhou

10PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyMedical infection agents (incl. prions)Gene and molecular therapyMedical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 19, 2026
Finite-Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia-A Pilot Study.

|Feb 03, 2025
Moderate-To-Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts.

Gaixiang Xu, Xingnong Ye, Yudi Zhang

|Apr 17, 2024
RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells.

Shuanghong Zhu, Yingwan Luo, Kongfei Li

|Dec 14, 2022
15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study.

Chen Mei, Li Ye, Yanling Ren

|Oct 31, 2022
Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome.

Yanling Ren, Wei Lang, Chen Mei

|Feb 20, 2021
Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes.

Xuefen Yan, Lu Wang, Lingxu Jiang

Pageof 2

Frequent Collaborators

7 joint publications

Yanling Ren

6 joint publications

Hongyan Tong

5 joint publications

Jie Jin

4 joint publications

Chen Mei